The Latest Cardiac and Vascular News
SANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”). The Neovasc Reducer System (the “Reducer”) […]
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million in the fourth quarter of 2022 (91% growth […]
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all […]
VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New […]
Neovasc’s Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Full Year 2023 Revenue Guidance SANTA CLARA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of […]
VANCOUVER and MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal clinical trial the Company is executing for the Neovasc Reducer™ (“Reducer”) towards an approval […]
VANCOUVER and MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal – Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy […]
VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third […]
VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for […]
New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease VANCOUVER and MINNEAPOLIS, Sept. 20, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston. Prof. Shmuel Banai, MD, Neovasc […]
